$STRO

SUTRO BIOPHARMA, INC. (STRO): Submission of Matters to a Vote of Security Holders

SUTRO BIOPHARMA, INC. (STRO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001382101 0001382101 2026-06-05 2026-06-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2

Original reporting
Published Jun 8, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 9, 2026, 8:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$STRO
Neutral
medium confidence
Mentioned
$STRO
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$STRONeutralLow
01

Why it matters

The disclosure confirms the board nominees were elected, Ernst & Young LLP was ratified as independent auditor for 2026, and the advisory say-on-pay proposal passed (non-binding).

02

Market read

Provides verified governance outcomes that may slightly influence sentiment but lacks new operating/financial catalysts.

03

What to watch

Traders may instead focus on whether any director contests or say-on-pay opposition could foreshadow future activism or changes in compensation strategy, though no such signal is quantified beyond vote counts here.

Relevance 6/10Novelty 5/10Timing: after-hours / filed June 8, 2026

Background

The article is an SEC Form 8-K (Item 5.07) reporting the outcomes of Sutro Biopharma’s 2026 annual stockholder meeting held June 5, 2026.

Company-level read

Ticker impact

$STRONeutralMedium confidence
Context

Sutro Biopharma filed an 8-K detailing results of its June 5, 2026 annual meeting, including director elections and auditor ratification.

Expected impact

Low likelihood of a sustained move; any reaction is likely limited to short-term sentiment around governance outcomes.

Evidence & confidence

The filing is a primary SEC disclosure of voting results, but it does not include new financial guidance, clinical data, or material transactions.

Market effects

Minimal read-across; governance vote outcomes are generally company-specific for small/mid-cap biopharma.

None.

None.

Counterpoint

Because the items are standard (director election, auditor ratification, non-binding say-on-pay), the market may ignore the details unless vote margins signal broader shareholder dissatisfaction.

Key entities

  • Sutro Biopharma, Inc.

    Nasdaq-listed biopharma company filing the 8-K with annual meeting voting results.

  • Ernst & Young LLP

    Independent registered public accounting firm ratified for the fiscal year ending Dec. 31, 2026.

Related articles

$STROMed

SUTRO BIOPHARMA, INC. (STRO): Results of Operations and Financial Condition

SUTRO BIOPHARMA, INC. (STRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study – Encouraging early clinical activity including confirmed and ongoing unconfirmed partial responses with favorable tolerability, and pharmacokinetics (PK

$LLYLow

Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020

Eli Lilly (LLY) broke ground on a $6.5B Houston facility to manufacture active pharmaceutical ingredients, including Foundayo (orforglipron), a GLP-1 drug for weight management. The site, part of Lilly's $50B U.S. investment, will create 600+ jobs and is supported by a $12.5M workforce training initiative with San Jacinto College. Foundayo is under regulatory review in over 40 countries, with global rollout targeted for 2027.

$SLFMed

Sun Life announces intention to redeem Series 2021-1 Subordinated Unsecured 2.46% Fixed/Floating Debentures

Sun Life Financial Inc. (SLF) announced plans to redeem $500 million in Series 2021-1 Subordinated Unsecured 2.46% Fixed/Floating Debentures on November 18, 2026. The redemption will be funded from existing cash and liquid assets, with holders receiving the principal amount plus accrued interest. After redemption, interest will cease to accrue, and holders will not retain any rights.

$CNHMedAI 8/10

Pricing of CNH Industrial Capital Canada Ltd. Cdn$200 million notes due 2028 and Cdn$350 million notes due 2030

CNH Industrial N.V. (CNH) announced its subsidiary, CNH Industrial Capital Canada Ltd., priced Cdn$200M 4.00% notes due 2028 and Cdn$350M 4.40% notes due 2030. Proceeds will be used for working capital and general corporate purposes. The notes are senior unsecured obligations and are guaranteed by CNH Industrial's subsidiaries. The offering is expected to close on September 25, 2026, subject to customary conditions.